Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

U2OS cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (7) Bacterial (1) Calcium Channel (1) CDK (3) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (4) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) G protein-coupled Bile Acid Receptor 1 (1) Glucocorticoid Receptor (1) GPR55 (1) HDAC (1) Histone Methyltransferase (3) IKK (1) Isotope-Labeled Compounds (1) Kinesin (1) LPL Receptor (1) Microtubule/Tubulin (1) NAMPT (2) NF-κB (1) Oxidative Phosphorylation (4) Reactive Oxygen Species (1) SGK (1) Smo (1) TGF-β Receptor (1) Topoisomerase (1) ULK (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (3) Endocrinology (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (6) Neurological Disease (2)

By Targets:

Apoptosis (3)

Autophagy (7)

Bacterial (1)

Calcium Channel (1)

CDK (3)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (4)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (1)

G protein-coupled Bile Acid Receptor 1 (1)

Glucocorticoid Receptor (1)

GPR55 (1)

HDAC (1)

Histone Methyltransferase (3)

IKK (1)

Isotope-Labeled Compounds (1)

Kinesin (1)

LPL Receptor (1)

Microtubule/Tubulin (1)

NAMPT (2)

NF-κB (1)

Oxidative Phosphorylation (4)

Reactive Oxygen Species (1)

SGK (1)

Smo (1)

TGF-β Receptor (1)

Topoisomerase (1)

ULK (1)

By Research Areas:

Cancer (22)

Cardiovascular Disease (3)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (6)

Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19979

RCM-1 2 Publications Verification	Others	Cancer
RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC₅₀ of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research .

HY-124132

Autophagy-IN-4	Autophagy	Cancer
Autophagy-IN-4 (Compound 34) is an autophagy inhibitor, with an EC₅₀ of 0.5 μM and a LD50 of 27 μM for U2OS cells .

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P3731

Cdk2/Cyclin Inhibitory Peptide II	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-N10073

Eupahualin C	Others	Cancer
Eupahualin C is a sesquiterpene lactone that can be isolated from Eupatorium hualienense. Eupahualin C shows cytotoxicity to K562 and U2OS cancer cells .

HY-169053

SU1261	IKK NF-κB	Cancer
SU1261 is an IKK inhibitor with K_i values of 10 nM and 680 nM for IKKα and IKKβ, respectively. SU1261 can inhibit non-canonical NF-κB signaling in U2OS osteosarcoma cells .

HY-163499

NAMPT activator-7	NAMPT	Cancer
NAMPT activator-7 (Compound 232) is an activator for nicotinamide phosphoribosyltransferase (NAMPT), with EC₅₀ < 0.5 μM. NAMPT activator-7 activates NAMPT in cells U2OS with cellular EC₅₀ of < 0.5 μM .

HY-163500

NAMPT activator-8	NAMPT	Cancer
NAMPT activator-8 (Compound 278) is an activator for nicotinamide phosphoribosyltransferase (NAMPT), with EC₅₀ < 0.5 μM. NAMPT activator-8 activates NAMPT in cells U2OS with cellular EC₅₀ of < 0.5 μM .

HY-161863

Tubulin polymerization-IN-67	Microtubule/Tubulin Reactive Oxygen Species Apoptosis	Cancer
Tubulin polymerization-IN-67 (Compound 5h) is an inhibitor for tubulin polymerization on colchicine binding site with an IC₅₀ of 2.92 μM. Tubulin polymerization-IN-67 inhibits the proliferation of cancer cells HT29, A549, U2OS, MG-63 and HeLa with IC₅₀s of 0.12-4.13 μM. Tubulin polymerization-IN-67 arrests the cell cycle at G2/M phase, induces apoptosis in cell U2OS, inhibits the cell migration of A549. Tubulin polymerization-IN-67 reduces the mitochondrial membrane potential (MMP) and increase intracellular ROS, inhibits the angiogenesis in HUVECs. Tubulin polymerization-IN-67 exhibits antitumor efficacy in mice

HY-163518

Antitumor agent-153	E1/E2/E3 Enzyme	Cancer
Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity .

HY-161628

Tapcin	Topoisomerase	Cancer
Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC₅₀ of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC₅₀s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model .

HY-111083

ML191 CID23612552	GPR55	Others
ML-191 is an antagonist of GPR55. It inhibits GPR55 signaling induced by lysophosphatidylinositol (EC₅₀=1.076 µM in U2OS cells overexpressing GPR55). ML-191 inhibits LPI-induced phosphorylation of ERK1/2 (IC₅₀=328 nM) and receptor-dependent translocation of PKCβII when used at a concentration of 30 µM .

HY-128221

SGK1-IN-5	SGK	Inflammation/Immunology
SGK1-IN-5 (Compound 1) is an inhibitor for serum and glucocorticoid regulated kinase SGK 1 with an IC₅₀ of 3 nM. SGK1-IN-5 inhibits SGK-1 dependent phosphorylation of GSK3β in U2OS cells with an IC₅₀ of 1.4 μM. SGK1-IN-5 can be used in research about osteoarthritis or rheumatism .

HY-103453

(R)-DPN	Estrogen Receptor/ERR	Endocrinology
(R)-DPN (compound 3) is a selective ERβ ligand with EC₅₀s of 2.9, 0.8 nM for ERα and ERβ, respectively. (R)-DPN shows a very high affinity and potency preference for ERβ over ERα. (R)-DPN shows cytoxicity for HEC-1 and U2OS cells with EC₅₀s of 286, 205 nM, respectively .

HY-14229

TGR5 Receptor Agonist 2 Publications Verification CCDC	G protein-coupled Bile Acid Receptor 1 Calcium Channel	Metabolic Disease
TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC₅₀s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca ²⁺ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity .

HY-161860

Antibacterial agent 233	Bacterial	Cancer
Antibacterial agent 233 (Compound 7c) exhibits inhibitory efficacy against Helicobacter pylori with MIC of 0.4-1.6 μg/mL. Antibacterial agent 233 inhibits jack bean urease (IC₅₀ is 0.27 μg/mL), changes the permeability of H. pylori cell membrane, causes the leakage of cellular contents. Antibacterial agent 233 exhibits metabolic stability in whole blood and artificial gastric fluid. Antibacterial agent 233 exhibits antitumor efficacy against U2OS in mice .

HY-114208A

BI-9321 trihydrochloride	Histone Methyltransferase	Cancer
BI-9321 trihydrochloride is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a K_d value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 trihydrochloride specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC₅₀ of 1.2 μM in U2OS cells .

HY-114208

BI-9321	Histone Methyltransferase	Cancer
BI-9321 is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a K_d value of 166 nM. BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC₅₀ of 1.2 μM in U2OS cells .

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .

HY-146080

Antitumor agent-61	Apoptosis	Cancer
Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC₅₀s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways .

HY-117846

MLAF50	DNA/RNA Synthesis	Cancer
MLAF50 is apotent REV1 UBM2-Ubiquitin interaction inhibitor. MLAF50 inhibits chromatin co-localization of REV1 with PCNA following DNA-damage induction .

HY-163460

MS8535	Epigenetic Reader Domain	Others
MS8535 is a SPIN1 selective inhibitor, with an IC₅₀ of 0.2 μM .

HY-115570

GW406108X 1 Publications Verification GW108X	Kinesin ULK Autophagy	Cancer
GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC₅₀ of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC₅₀ of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK .

HY-109015S

Tucidinostat-d4 Chidamide-d₄; HBI-8000-d₄; CS 055-d₄	Isotope-Labeled Compounds HDAC	Cancer
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

HY-148246

MU1700	TGF-β Receptor	Cancer
MU1700 is an orally active and potent ALK1/2 inhibitor with IC₅₀s of 13 nM and 6 nM, respectively. MU1700 shows cell membrane permeability and high brain permeability .

HY-134828

AZ506 2 Publications Verification	Histone Methyltransferase	Cancer
AZ506 is a potent SMYD2 inhibitor with an IC₅₀ of 17 nM. AZ506 inhibits SMYD2 methyltransferase activity in cells, leading to a decrease in the SMYD2-mediated methylation signal .

HY-148764

M47	Apoptosis	Cancer
M47 is a small molecule that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer .

HY-117213

Ex26 S1P1-IN-Ex26	LPL Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1 (S1P₁) antagonist (IC₅₀=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P₁ over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach .

HY-128892

EN6 3 Publications Verification	Autophagy	Neurological Disease
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .

HY-113596

Acetyl Coenzyme A trisodium 1 Publications Verification Acetyl-CoA trisodium	Oxidative Phosphorylation Endogenous Metabolite Autophagy	Metabolic Disease
Acetyl-coenzyme A (Acetyl-CoA) trisodium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trisodium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trisodium is also a key precursor of lipid synthesis .

HY-113596A

Acetyl coenzyme A lithium Acetyl-CoA lithium	Oxidative Phosphorylation Endogenous Metabolite Autophagy	Cardiovascular Disease Metabolic Disease
Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis .

HY-114293A

Acetyl coenzyme A trilithium Acetyl-CoA trilithium	Oxidative Phosphorylation Endogenous Metabolite Autophagy	Cardiovascular Disease Metabolic Disease
Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis .

HY-114293

Acetyl coenzyme A Acetyl-CoA	Oxidative Phosphorylation Endogenous Metabolite Autophagy	Cardiovascular Disease Metabolic Disease
Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .

HY-B0603

Fluticasone	Smo Glucocorticoid Receptor	Infection Inflammation/Immunology Endocrinology
Fluticasone is an inhaled corticosteroid used for respiratory research. Fluticasone is a Smo agonist with an IC₅₀ value of 99 nM. Fluticasone activates Hedgehog signaling and promotes the proliferation of primary neuronal stem or precursor cells .

Cat. No.	Product Name	Type

HY-113596A

Acetyl coenzyme A lithium Acetyl-CoA lithium	Drug Delivery
Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis .

Acetyl coenzyme A lithium

Acetyl-CoA lithium

Drug Delivery

Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis .

Cat. No.	Product Name	Target	Research Area